Surrozen, Inc. (NASDAQ:SRZN) Receives Average Rating of “Moderate Buy” from Analysts

Posted by Brian Himes on Aug 31st, 2026

Surrozen, Inc. (NASDAQ:SRZN – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the seven analysts that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, four have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $45.00.

Several research firms have recently weighed in on SRZN. HC Wainwright reaffirmed a “buy” rating and issued a $44.00 target price on shares of Surrozen in a report on Monday, August 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Surrozen in a report on Friday, July 17th. William Blair initiated coverage on shares of Surrozen in a research report on Thursday, August 20th. They issued an “outperform” rating and a $51.00 price target on the stock. Finally, Zacks Research raised shares of Surrozen from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 28th.

Get Our Latest Stock Report on SRZN

Insider Activity at Surrozen

In related news, major shareholder Tcg Crossover Gp Ii, Llc sold 325,000 shares of the stock in a transaction that occurred on Wednesday, July 22nd. The stock was sold at an average price of $21.25, for a total transaction of $6,906,250.00. Following the sale, the insider directly owned 574,047 shares in the company, valued at $12,198,498.75. This represents a 36.15% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 31.74% of the stock is owned by insiders.

Hedge Funds Weigh In On Surrozen

Several institutional investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. grew its holdings in shares of Surrozen by 50.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 1,500 shares of the company’s stock worth $34,000 after purchasing an additional 500 shares during the last quarter. California State Teachers Retirement System bought a new position in shares of Surrozen in the second quarter valued at about $68,000. Persistent Asset Partners Ltd bought a new position in shares of Surrozen in the fourth quarter valued at about $99,000. Citadel Advisors LLC raised its holdings in shares of Surrozen by 32.8% in the third quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock valued at $179,000 after buying an additional 3,424 shares during the last quarter. Finally, Marshall Wace LLP acquired a new position in Surrozen during the 4th quarter worth about $247,000. Institutional investors own 66.57% of the company’s stock.

Surrozen Price Performance

Shares of SRZN stock opened at $22.42 on Monday. The stock’s fifty day simple moving average is $23.13 and its 200 day simple moving average is $25.68. The firm has a market cap of $260.30 million, a price-to-earnings ratio of -0.55 and a beta of 0.52. Surrozen has a one year low of $11.25 and a one year high of $35.00.

Surrozen (NASDAQ:SRZN – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.88. The company had revenue of $5.00 million during the quarter, compared to the consensus estimate of $0.47 million. On average, research analysts anticipate that Surrozen will post -7.62 earnings per share for the current year.

Surrozen Company Profile

(Get Free Report)

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.